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2Abstract
The fibroblast growth factor (FGF23) plasma level is high in cardiac and renal failure and is 
associated with poor clinical prognosis of these disorders. Both diseases are paralleled with 
hyperaldosteronism. Excessive FGF23 levels and hyperaldosteronism are further observed in 
Klotho-deficient mice. The present study explored a putative aldosterone sensitivity of Fgf23 
transcription and secretion and the putative involvement of the aldosterone sensitive serum &
glucocorticoid inducibe kinase SGK1 and SGK1 sensitive WUDQVFULSWLRQIDFWRU1)ț%and store 
operated Ca2+ entry (SOCE). Serum FGF23 levels were determined by ELISA in mice following 
sham treatment or exposure to deoxycorticosterone acetate (DOCA) or salt depletion. In
osteoblastic UMR106 cells transcript levels were quantified by qRT-PCR, cytosolic Ca2+
concentration utilizing Fura-2-fluorescence, and SOCE from Ca2+ entry following store 
depletion by thapsigargin. As a result, DOCA treatment and salt depletion of mice elevated the 
serum C-terminal FGF23 concentration. In UMR106 cells aldosterone enhanced and 
spironolactone decreased SOCE. Aldosterone further increased Fgf23 transcript levels in 
UMR106 cells, an effect reversed by mineralocorticoid receptor blockers spironolactone and
eplerenone, SGK1 inhibitor EMD638683, 1)ț%-inhibitor withaferin A, and Ca2+ channel 
blocker YM58483. In conclusion, Fgf23 expression is up-regulated by aldosterone, an effect 
sensitive to SGK1, 1)ț%and store-operated Ca2+ entry.
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3Introduction
Regulation of calcium phosphate metabolism involves FGF23 (fibroblast growth 
factor 23), which is mainly released from bone cells [1]. FGF23 decreases formation and fosters 
inactivation of 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) by down-regulating UHQDO Į
hydroxylase (Cyp27b1) and up-regulating 25-hydroxyvitamin D 24-hydroxylase (Cyp24a1)
[2]. FGF23 thus lowers serum levels of 1,25(OH)2D3 [3,4], which stimulates renal and 
intestinal phosphate and calcium transport[5,6] . FGF23 deficiency is followed by increase of
plasma 1,25(OH)2D3 levels, hyperphosphatemia, and hypercalcemia leading to vascular 
calcification, rapid aging and a substantial decrease of the life span [2]. Vascular calcification is 
stimulated by hyperphosphatemia [7], a predictor of mortality [8] and by aldosterone [9], which 
similarly impacts on life span [9].
Excessive plasma FGF23 levels are observed and are associated with accelerated 
disease progression, morbidity and/or mortality in several clinical disorders including cardiac 
failure [10,11], acute renal failure [12], chronic kidney disease [11,13,14], diabetic 
nephropathy [15] and hepatic failure [16]. The pathophysiological significance of enhanced 
FGF23 formation, has, however, remained ill-defined [17,18] and little is known about 
mechanisms accounting for the up-regulation of FGF23 release in these clinical disorders.
Most recently, Fgf23 transcription has been shown to be stimulated by an increase in the 
cytosolic Ca2+ concentration ([Ca2+]i) secondary to upregulation of store operated Ca2+ entry 
(SOCE) [19], which is triggered by depletion of intracellular Ca2+ stores [20]. SOCE is 
accomplished by the calcium release-activated channel (CRAC) moiety Orai1 (CRACM1)
[21], which is activated by stromal interaction molecule 1 (STIM1) [22]. Expression and 
activity of Orai1 are up-regulated by the transcription IDFWRU1)ț%[23].
Regulators of 1)ț%LQFOXGHPLneralocorticoids [24,25]. In patients with non-ischemic 
cardiac disease and early chronic kidney disease high FGF23 plasma levels are associated with 
high plasma aldosterone concentrations [11].
The present study explored whether aldosterone modifies FGF23 release and, if so, 
whether the effect involves 1)ț% and Ca2+ entry.
Materials and Methods
Animal experiments
The animal experiments were conducted according to the German law for the welfare of 
animals and were approved by the state of Baden-Württemberg (Regierungspräsidium
Tübingen). Fifty μl blood was collected from male and female C57BL/6 mice (8-20 weeks old). 
Then, mice were sham-treated or treated with a single s.c. injection of deoxycorticosterone 
acetate (DOCA; 100 mg/kg b.w.; Sigma, Schnelldorf, Germany) or spironolactone (75 mg/kg 
b.w.; Sigma). Twelve hours after the injection, another 50 μl blood was collected. For the effect 
of low salt diet on FGF23 release, male and female mice (2-13 months old) were fed a control 
diet or a low salt diet (containing <0.2% Na+ and Cl-; Altromin, Lage, Germany) for a total of 
7-14 days and subsequently 50 μl blood were collected. Serum C-terminal FGF23 was 
determined with an ELISA kit (Immutopics, San Clemente, USA). Serum aldosterone and 
corticosterone were quantified by means of kits from IBL (Hamburg, Germany) according to 
the manufacturers’ protocol.
Cell culture
UMR106 rat osteosarcoma cells were cultured in DMEM high glucose medium 
supplemented with 10% FCS and 1% penicillin/streptomycin under standard culture 
4conditions. Cells were pretreated with 100 nM 1,25(OH)2D3 (Sigma) for 42 h. Then, 100 nM 
aldosterone (Sigma) was added without or with 10 μM spironolactone (Sigma), 10 μM 
eplerenone (Sigma), 100 nM YM58483 (TOCRIS), 500 nM withaferin A (TOCRIS), or 50 μM 
SGK1 inhibitor EMD638683 (Merck Darmstadt, Germany) for 6 h.
For the calcium measurements and the quantification of Orai1 transcripts, cells were 
WUHDWHG ZLWK  Q0 DOGRVWHURQH 6LJPD RU  ȝ0 VSLURQRODFWRQH 6LJPD IRU  K LQ
serum-free medium.
Quantification of mRNA expression
For the mRNA expression analysis in UMR106 cells, the final volume of the qRT-PCR 
reaction mixture was 20 μl and contained: 2 μl cDNA, 1 μM of each primer, 10 μl GoTaq 
Master Mix Green (Promega), and sterile water up to 20 μl. PCR conditions were 95°C for 3 
min, followed by 40 cycles of 95°C for 10 s, 58°C for 30 s. Quantitative RT-PCR was 
performed on a BioRad iCycler iQTM Real-Time PCR Detection System (Bio-Rad 
Laboratories, Munich, Germany).
For the determination of Fgf23 transcripts in mouse bone, bone was homogenized in 
liquid nitrogen using mortar and pestle. Total mRNA from bone was extracted with TRIzol 
(Invitrogen, Switzerland) followed by purification with RNeasy Mini Kit (Qiagen, 
Switzerland) according to the manufacturer’s protocol. DNAse digestion was performed using 
the RNase-free DNAase Set (Qiagen, Switzerland). Total RNA extractions were analyzed for 
quality, purity, and concentration using the NanoDrop ND-1000 spectrophotometer 
(Wilmington, Germany). RNA samples were diluted to a final concentration of 100 ng/μl and 
cDNA was prepared using the TaqMan Reverse Transcriptase Reagent Kit (Applied 
Biosystems, Roche, Foster City, CA). In brief, in a reaction volume of 40 μl, 300 ng of RNA 
was used as template and mixed with the following final concentrations of RT buffer (1x): 
MgCl2 (5.5 mmol/l), random hexamers (2.5 μmol/l), dNTP mix (500 μmol/l each), RNase 
inhibitor (0.4 U/μl), multiscribe reverse transcriptase (1.25 U/μl), and RNAse-free water. 
Reverse transcription was performed with thermocycling conditions of 25°C for 10 min, 48°C 
for 30 min, and 95°C for 5 min on a thermocycler (Biometra, Göttingen, Germany). 
Semi-quantitative real-time PCR (RT-PCR) was performed on the ABI PRISM 7700 Sequence 
Detection System (Applied Biosystems). Primers were chosen to spanning intron–exon 
boundaries to exclude genomic DNA contamination. Probes were labeled with the reporter dye 
FAM at the 5’-end and the quencher dye TAMRA at the 3’-end (Microsynth, Balgach, 
Switzerland). Real-time PCR reactions were performed using KAPA PROBE FAST qPCR Kit 
(Kapa Biosystems, USA).
The following primers were used:
Rat Tbp (TATA box-binding protein):
forward (5'-3'): ACTCCTGCCACACCAGCC
reverse (5'-3'): GGTCAAGTTTACAGCCAAGATTCA
Rat Fgf23
forward (5'-3'): TGGCCATGTAGACGGAACAC
reverse (5'-3'): GGCCCCTATTATCACTACGGAG
Rat Orai1
forward (5'-3'): CGTCCACAACCTCAACTCC
reverse (5'-3'): AACTGTCGGTCCGTCTTAT
Mouse Fgf23
forward (5'-3'): TCGAAGGTTCCTTTGTATGGAT
reverse (5'-3'): AGTGATGCTTCTGCGACAAGT
Calculated mRNA expression levels were normalized to the expression levels of Tbp (in rat 
derived cell lines) or HPRT/18S (in mice) of the same cDNA sample. Relative quantification of 
gene expression was performed using the ǻǻ&Wmethod.
5Measurement of intracellular Ca2+
To determine the cytosolic Ca2+ concentration ([Ca2+]i), UMR106 cells were loaded 
with Fura-2/AM (2 μM, Molecular Probes, Göttingen, Germany) for 15 min at 37°C. 
Fluorescence measurements were carried out with an inverted phase-contrast microscope 
(Axiovert 100, Zeiss, Oberkochen, Germany). Cells were excited alternatively at 340 or 380 nm 
and the light was deflected by a dichroic mirror into either the objective (Fluar 40×/1.30 oil, 
Zeiss, Oberkochen, Germany) or a camera (Proxitronic, Bensheim, Germany). Emitted 
fluorescence intensity was recorded at 505 nm. Data acquisition was accomplished by using 
specialized computer software (Metafluor, Universal Imaging Downingtown, USA). As a 
measure for the increase in the cytosolic Ca2+ concentration, the slope and peak of the changes 
in the 340/380 nm ratio were determined in each experiment. 
To determine SOCE, intracellular Ca2+ was measured before and after removal of 
extracellular Ca2+ (and addition of 0.5 mM EDTA), followed by addition of thapsigargin (1 
μM) and subsequent re-addition of extracellular Ca2+ to Ringer solution, composed of (in mM):
125 NaCl, 5 KCl, 1.2 MgSO4, 32.2 HEPES (NaOH/pH 7.4), 2 Na2HPO4, 0 or 2 CaCl2 and 0.5 
or 0 EGTA, respectively, and 5 glucose.
Immunofluorescence
UMR106 cells treated with 100 nM aldosterone were cultured on 4-well chamber slides 
(Thermo scientific), washed, and fixed with 4% paraformaldehyde for 30 min at room 
temperature. For blocking unspecific binding, UMR106 cells were incubated with 3% Albumin
Fraction V (Carl Roth, Karlsruhe, Germany), 5% normal goat serum (Sigma, Schnelldorf, 
Germany), and 0.5% Triton in PBS (PAA, Cölbe, Germany) for 30 min at room temperature. 
Then, the cells were exposed to rabbit anti-p65 (1:1000, Genetex, Irvine, USA) at 4°C in a 
humidified chamber overnight. The cells were rinsed four times with PBS and incubated with 
DyLight® 488-conjugated goat anti-rabbit antibody (1:3000, BIOZOL, Eching, Germany) for 
1 h at room temperature. After four washing steps the nuclei were stained with DRAQ-5 dye 
(1:400; BIOZOL) for 30 min at room temperature. The slides and coverslips were mounted 
with FluorSaveTM Reagent (Calbiochem, Darmstadt, Germany). Images were taken on a LSM 5 
EXCITER confocal laser scanning microscope (Zeiss, Germany) with a water-immersion 
Plan-Neofluar 40×/1.3 NA differential interference contrast and analyzed with the instrument's 
software.
Statistics
Data are provided as means ± SEM, n represents the number of independent 
experiments. All data were tested for significance using unpaired Student t-test or ANOVA.
Only results with p < 0.05 were considered statistically significant.
Results
In order to test for an effect of mineralocorticoids on FGF23 release, a single dose of 
DOCA (100 mg/kg b.w. s.c.) or vehicle was injected into wild type mice. Twelve hours later the 
serum C-terminal FGF23 (cFGF23) level was determined. As illustrated in Fig. 1A, the 
injection of DOCA was followed by a marked and significant increase in the serum cFGF23 
concentration. In a second series of experiments, mice were fed a low salt diet. As expected, 
this diet induced an elevation of the serum aldosterone level (889 ± 217 pg/ml; n=5) compared 
to standard chow-fed mice (268 ± 27 pg/ml; n=5; p<0.01). The diet did not significantly affect 
the serum corticosterone level (low salt diet: 162 ± 32 ng/ml; n=5; standard chow: 120 ± 31 
ng/ml; n=5). As illustrated in Fig 1B, the low salt diet also elevated the serum concentration of 
6C-terminal FGF23. The main site of FGF23 formation is the bone. Accordingly, we found a 
higher level of Fgf23 transcripts in bone from DOCA-treated mice compared to untreated mice 
(Fig. 1C). Treatment with spironolactone (12 h, 75 mg/kg b.w.) did, however, not significantly 
influence the serum FGF23 concentration (control: 201 ± 6 pg/ml, n=5; spironolactone: 332 ± 
65 pg/ml, n=5). Similarly, spironolactone treatment did not block the increase in serum FGF23 
induced by low-salt diet (serum FGF23 before low-salt diet: 134 ± 15 pg/ml; serum FGF23 
after two weeks of low-salt diet: 194 ± 13 pg/ml; n=8; p<0.01).
Fluorescence optics was employed to test whether aldosterone modifies the intracellular 
Ca2+ concentration ([Ca2+]i). Store-operated Ca2+ entry (SOCE) requires depletion of intracellular 
Ca2+ stores which was accomplished by inhibition of the sarcoendoplasmic Ca2+ ATPase 
(SERCA) with thapsigargin (1 μM) in the absence of extracellular Ca2+. SOCE was estimated 
from the increase in [Ca2+]i following re-addition of extracellular Ca2+. UMR106 cells were 
treated with aldosterone or the mineralocorticoid receptor antagonist spironolactone and 
intracellular Ca2+ concentrations ([Ca2+]i) were determined prior to and following removal of 
extracellular Ca2+, addition of thapsigargin, and re-addition of extracellular Ca2+. As illustrated in 
Fig. 2A-C, aldosterone did not significantly modify the thapsigargin-induced increase in [Ca2+]i
but significantly enhanced the elevation of [Ca2+]i following re-addition of extracellular Ca2+. The 
aldosterone antagonist spironolactone did not significantly modify the thapsigargin-induced 
increase in [Ca2+]i, but significantly blunted the increase in [Ca2+]i following re-addition of 
extracellular Ca2+ (Fig. 2D-F).
A further series of experiments explored whether the influence of aldosterone and 
spironolactone on Ca2+ signaling in UMR106 cells was involved in the transcriptional 
regulation of Fgf23. Aldosterone (Fig. 3A) significantly elevated the Orai1 transcript level in 
UMR106 cells. Moreover, aldosterone up-regulated the transcription of Fgf23, an effect 
virtually abrogated by spironolactone, the Orai inhibitor YM58483, or the 1)ț% LQKLELWRU
withaferin A (Fig. 3B). The dose-response curve of the aldosterone effect on FGF23 is shown in 
Fig 3C. The aldosterone antagonist eplerenone similarly reversed the aldosterone effect on 
Fgf23 (Fig. 3D). Immunofluorescence confirmed activation of 1)ț% E\ DOGRVWHURQH LQ
UMR106 cells (Fig. 3E).
A possible mediator of the aldosterone effect on Orai1 is SGK1 which has been shown to 
up-regulate this channel. Employing qRT-PCR we indeed found a positive effect of aldosterone 
on the Sgk1 transcript level in UMR106 cells (control: 0.73 ± 0.04 a.u., n=12; 100 nM 
aldosterone: 1.02 ± 0.05 a.u.,n=12; p<0.001). Moreover, aldosterone failed to stimulate Fgf23 
expression in the presence of a SGK1 inhibitor (Fig. 3F).
The dose effects of mineralocorticoid antagonism with spironolactone or eplerenone are 
displayed in Fig. 4A and 4B, respectively. Notably, the effect of higher aldosterone concentrations 
on FGF23 transcription were also blocked by the glucocorticoid antagonist mifepristone (Fig. 4C).
Discussion
The present observations reveal that mineralocorticoids may contribute to the regulation of 
Fgf23 transcription and release in vivo. They further shed some light on the cellular mechanisms 
involved. According to previous observations [19] FGF23 release is stimulated by an increase in 
the cytosolic Ca2+ concentration ([Ca2+]i), which could be triggered by store operated Ca2+ entry 
(SOCE). Aldosterone increased and spironolactone decreased SOCE and thus modified
transcription of Fgf23. SOCE is mediated by isoforms of the channel Orai (CRAC) [21], which are 
activated upon store depletion by STIM1 and STIM2  [22]. UMR106 cells express high levels of 
Orai1 and STIM2 [19]. The expression of Orai1 is stimulated by the transcription factor 1)ț%
[23], which thus impacts on Fgf23 expression [19]. Aldosterone has previously been shown to 
up-UHJXODWH 1)ț% [24,26]. The present study reveals that the effect of aldosterone on Fgf23 
7transcript levels LVDEURJDWHGE\1)ț%LQKLELWRUV7KHSUHVHQWREVHUYDWLRQVGRKRZHYHUQRWUXOH
out WKDW1)ț%SOD\VDSHUPLVVLYHUROHLQWKHUHJXODWLRQRI)*)H[SUHVVLRQDQGUHOHDVH
As aldosterone is effective at concentrations as low as 1 nM, the effect of aldosterone is 
most likely - at least in part - due to stimulation of mineralocorticoid receptors. The effect of 
higher aldosterone concentrations is, however, blunted by the glucocorticoid antagonist 
mifepristone, an observation pointing also to an involvement of glucocorticoid receptors. 
Noteworthy, both, mineralocorticoid and glucocorticoid receptors upregulate the serum & 
glucocorticoid inducible kinase (SGK1) which has been shown to induce Orai1-dependent Ca2+ 
entry by activating 1)ț%[27]. Along those lines, pharmacological SGK1 inhibition reversed the 
effect of aldosterone on Fgf23 expression. Spironolactone treatment, however, did not reverse the 
increase in serum FGF23 induced by low-salt diet. Thus, the possibility must be kept in mind that 
mechanisms other than mineralocorticoid receptor activation contribute to the up-regulation of 
FGF23 release during dehydration. Along those lines, renal klotho expression is not only 
down-regulated by mineralocorticoids but as well by ADH [28].
Chronic kidney disease [29-31], heart failure [32-34], diabetic nephropathy [35], and 
hepatic failure [34] are all characterized by hyperaldosteronism. According to the present 
observations, the high FGF23 plasma concentration in heart failure [10,11], acute renal failure 
[12], chronic kidney disease [11,13,14], diabetic nephropathy [15] and hepatic failure [16]
could at least in part be secondary to the hyperaldosteronism associated with these diseases.
The effect of aldosterone may at least partially be mediated by the serum & glucocorticoid 
inducible kinase SGK1, which is up-regulated by aldosterone and during diabetes [36] and is 
known to up-regulate Orai1 [23].
In conclusion, aldosterone is a powerful stimulator of FGF23 formation in vitro and in 
vivo$OGRVWHURQHLVDWOHDVWSDUWLDOO\HIIHFWLYHE\1)ț%GHSHQGHQWXS-regulation of Orai1 with 
subsequent enhancement of store operated Ca2+ entry.
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Figure Legends
Fig. 1. Effect of aldosterone on the FGF23 serum level. A. Arithmetic means ± SEM (n=9-11) 
of the serum FGF23 concentration in wild type mice sham-treated (white bar) or treated with a 
single DOCA injection (100 mg/kg b.w. s.c.) for 12 hrs (black bar). B. Arithmetic means ± 
SEM (n=11) of the serum FGF23 concentration in wild type mice treated with normal diet 
(white bar) or with low salt diet for 7-14 days (black bar). C. Arithmetic means ± SEM (n=4-5) 
of the relative Fgf23 mRNA abundance in wild type mice sham-treated (white bar) or treated 
with a single DOCA injection (100 mg/kg b.w. s.c.) for 12 hrs (black bar). *(p<0.05), 
**(p<0.001), ***(p<0.001), indicate significant difference.  
Fig. 2. Effect of aldosterone and spironolactone on SOCE. A,D. Representative original 
tracings showing intracellular Ca2+ concentrations ([Ca2+]i) in Fura-2/AM loaded UMR106
cells prior to and following removal of extracellular Ca2+, addition of the sarco-endoplasmic 
Ca2+ ATPase (SERCA) inhibitor thapsigargin (1 μM) and readdition of extracellular Ca2+, all in 
the absence (open circles) and presence (closed circles) of aldosterone (A, 100 nM, 24 h), or 
spironolactone (D, 10 μM, 24 h). B,C,E,F. Arithmetic means ± SEM of the peak (left) and 
slope (right) values of the [Ca2+]i increase following addition of thapsigargin reflecting Ca2+
release from intracellular stores (B,E) and of [Ca2+]i increase following readdition of 
extracellular Ca2+ reflecting store operated Ca2+ entry (C,F) in UMR106 cells incubated 
without (white bars) or with (black bars) aldosterone (B-C, 100 nM, 24 h, n=72-80), or 
spironolactone (E-F, 10 μM, 24 h, n=121-133).*(p<0.05), ***(p<0.001) indicate significant 
difference (student's t-test).  
Fig.3. Effect of aldosterone on Fgf23 transcript levels in UMR106 cells with or without 
spironolactone, eplerenone, YM58483 and withaferin A. A. Arithmetic means ± SEM (n=18) 
of Orai1 mRNA abundance (relative to Tbp mRNA) in UMR106 cells incubated without (white 
bar) or with (black bar) aldosterone (100 nM, 24 h). B. Arithmetic means ± SEM (n=7) of Fgf23 
mRNA abundance (relative to Tbp mRNA) in UMR106 cells incubated without (white bars) or 
with (black bars) aldosterone (100 nM, 6 h) in the absence (left bars) or presence (right bars) of 
spironolactone (10 μM) of Orai inhibitor YM58483 (100 nM) or of 1)ț%LQKLELWRUwithaferin A 
(500 nM). C. Arithmetic means ± SEM (n=36-37) of Fgf23 mRNA abundance (relative to Tbp 
mRNA) in UMR106 cells incubated without (white bars) or with (black bars) aldosterone (6 h) at 
the indicated concentration. D. Arithmetic means ± SEM (n=11) of Fgf23 mRNA abundance 
(relative to Tbp mRNA) in UMR106 cells incubated without (white bars) or with (black bars) 
aldosterone (100 nM, 6 h) in the absence (left bars) or presence (right bars) of eplerenone (10 μM).
E. Original immunofluorescence images demonstrating nuclear staining (Draq5; Red; left 
images), p65-VSHFLILFVWDLQLQJ1)ț%; Green middle images), and an overlay of both, nuclear 
and p65-specific staining (right images) in UMR106 cells incubated without (upper images) or 
with (lower images) aldosterone (100 nM, 24 h) Scale bar: 20 ȝP. F. Arithmetic means ± SEM 
(n=12) of Fgf23 mRNA abundance (relative to Tbp mRNA) in UMR106 cells incubated without 
(white bars) or with (black bars) aldosterone (100 nM, 6 h) in the absence (left bars) or presence 
(right bars) of SGK1 inhibitor EMD638683 (50 μM). *, **, *** (p<0.05, p<0.01, p<0.001)
indicate difference from control. ### (p<0.001) indicates difference from aldosterone alone.
Fig.4. Dose response relationship of mineralocorticoid and glucocorticoid antagonism with 
the aldosterone effect on Fgf23 transcription. Arithmetic means ± SEM of Fgf23 mRNA 
abundance (relative to Tbp mRNA) in UMR106 cells incubated with spironolactone (A; n=15), 
eplerenone (B; n=9-11), or mifepristone (C; n= 4-6) at the indicated concentration without 
(white bars) or with (black bars) 100 nM aldosterone (6 h). *, ** (p<0.05, p<0.01) indicate
difference from control. #, ### (p<0.05, p<0.001) indicate difference from aldosterone alone.
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